Literature DB >> 21729656

Consensus statement on palliative lung radiotherapy: third international consensus workshop on palliative radiotherapy and symptom control.

George Rodrigues1, Fergus Macbeth, Bryan Burmeister, Karie-Lynn Kelly, Andrea Bezjak, Corey Langer, Carol Hahn, Benjamin Movsas.   

Abstract

The purpose of this work is to disseminate a consensus statement on palliative radiotherapy (RT) of lung cancer created in conjunction with the Third International Lung Cancer Consensus Workshop. The palliative lung RT workshop committee agreed on 5 questions relating to (1) patient selection, (2) thoracic external-beam radiation therapy (XRT) fractionation, (3) endobronchial brachytherapy (EBB), (4) concurrent chemotherapy (CC), and (5) palliative endpoint definitions. A PubMed search for primary/cross-referenced practice guidelines, consensus statements, meta-analyses, and/or systematic reviews was conducted. Final consensus statements were created after review and discussion of the available evidence. The following summary statements reflect the consensus of the international working group. 1. Key factors involved in the decision to deliver palliative RT include performance status, tumor stage, pulmonary function, XRT volume, symptomatology, weight loss, and patient preference. 2. Palliative thoracic XRT is generally indicated for patients with stage IV disease with current/impending symptoms and for patients with stage III disease treated for palliative intent. 3. There is no evidence to routinely recommend EBB alone or in conjunction with other palliative maneuvers in the initial palliative management of endobronchial obstruction resulting from lung cancer. 4. There is currently no evidence to routinely recommend CC with palliative-intent RT. 5. Standard assessment of symptoms and health-related quality of life (QOL) using validated questionnaires should be carried out in palliative RT lung cancer trials. Despite an expanding literature, continued prospective randomized investigations to better define the role of XRT, EBB, and CC in the context of thoracic palliation of patients with lung cancer is needed.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21729656     DOI: 10.1016/j.cllc.2011.04.004

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  10 in total

1.  Use of radiation therapy in the last 30 days of life among a large population-based cohort of elderly patients in the United States.

Authors:  B Ashleigh Guadagnolo; Kai-Ping Liao; Linda Elting; Sharon Giordano; Thomas A Buchholz; Ya-Chen Tina Shih
Journal:  J Clin Oncol       Date:  2012-11-19       Impact factor: 44.544

2.  Non-oncologist Physician Knowledge of Radiation Therapy at an Urban Community Hospital.

Authors:  Evan Siau; Hernando Salazar; Jonathan Livergant; Jonathan Klein
Journal:  J Cancer Educ       Date:  2021-02       Impact factor: 2.037

Review 3.  Management of non-small cell lung cancer with EGFR mutation: the role of radiotherapy in the era of tyrosine kinase inhibitor therapy-opportunities and challenges.

Authors:  Bing Xia; Shirong Zhang; Shenglin Ma
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

4.  Expectations about the effectiveness of radiation therapy among patients with incurable lung cancer.

Authors:  Aileen B Chen; Angel Cronin; Jane C Weeks; Elizabeth A Chrischilles; Jennifer Malin; James A Hayman; Deborah Schrag
Journal:  J Clin Oncol       Date:  2013-06-17       Impact factor: 44.544

5.  Relationships between family physicians' referral for palliative radiotherapy, knowledge of indications for radiotherapy, and prior training: a survey of rural and urban family physicians.

Authors:  Robert A Olson; Sonca Lengoc; Scott Tyldesley; John French; Colleen McGahan; Jenny Soo
Journal:  Radiat Oncol       Date:  2012-05-18       Impact factor: 3.481

6.  Objective consensus from decision trees.

Authors:  Paul Martin Putora; Cedric M Panje; Alexandros Papachristofilou; Alan Dal Pra; Thomas Hundsberger; Ludwig Plasswilm
Journal:  Radiat Oncol       Date:  2014-12-05       Impact factor: 3.481

7.  Non-small cell lung cancer therapy: safety and efficacy in the elderly.

Authors:  Owen S Glotzer; Thomas Fabian; Anurag Chandra; Charles T Bakhos
Journal:  Drug Healthc Patient Saf       Date:  2013-04-22

8.  Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group.

Authors:  H H Strøm; R M Bremnes; S H Sundstrøm; N Helbekkmo; O Fløtten; U Aasebø
Journal:  Br J Cancer       Date:  2013-08-20       Impact factor: 7.640

9.  Patterns of prescribing radiotherapy and bevacizumab in nationwide practice - analysis of 101 designated cancer care hospitals in Japan.

Authors:  Yoichiro Tsukada; Fumiaki Nakamura; Momoko Iwamoto; Atsuro Terahara; Takahiro Higashi
Journal:  J Radiat Res       Date:  2015-12-09       Impact factor: 2.724

10.  Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev).

Authors:  Pierpaolo Pastina; Valerio Nardone; Cirino Botta; Stefania Croci; Paolo Tini; Giuseppe Battaglia; Veronica Ricci; Maria Grazia Cusi; Claudia Gandolfo; Gabriella Misso; Silvia Zappavigna; Michele Caraglia; Antonio Giordano; Donatella Aldinucci; Pierfrancesco Tassone; Pierosandro Tagliaferri; Luigi Pirtoli; Pierpaolo Correale
Journal:  Oncotarget       Date:  2017-08-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.